AU Australien
  • 24 - Tabak und verarbeitete Tabakersatzstoffe
  • 30 - Pharmazeutische Erzeugnisse

Nicotine-containing products intended to be used in vaping devices such as e-cigarettes, e-cigars and other electronic nicotine delivery systems (ENDs).

One of the possible reform options would also affect the importation of vaping devices that do not contain nicotine (ENNDs). TOBACCO AND MANUFACTURED TOBACCO SUBSTITUTES (HS 24); PHARMACEUTICAL PRODUCTS (HS 30)

Potential reforms to the regulation of nicotine vaping products - consultation paper

In notification G/TBT/N/AUS/151, it was advised that Australia is considering potential reforms primarily to the regulation of Electronic Nicotine Delivery Systems (ENDs). The scope of the proposed reforms has expanded to cover all vapes, including electronic non-nicotine delivery systems (ENNDs).

The proposed reforms to ENDs previously notified are still being pursued. However, subject to further consultation, it is now intended that all vapes (both e-liquids and devices used to produce vapour) will be prohibited unless they are therapeutic products to be used for smoking cessation or to treat nicotine addiction in accordance with Australia's therapeutic goods legislation. It is also intended to prohibit all single use disposable vapes.

It is proposed that this would involve:

·        Making changes to Australia's border controls to:

o   Prohibit the importation of all single use disposable vapes;

o   Prohibit the importation of all other vapes without an import permit. Permits would only be granted for therapeutic vapes (mainly ENDs) that comply with Therapeutic Goods Administration (TGA) requirements, including new pre-market requirements and a strengthened product standard regarding minimum quality and safety standards; and

o   Restrict individuals from importing therapeutic vapes for personal use under the Personal Importation Scheme.

·        Implementing equivalent restrictions on the manufacture and supply of vapes within Australia. It would only be permissible to manufacture and supply therapeutic vapes that comply with TGA requirements.

·        Ensuring therapeutic vapes are only available for the purpose of smoking cessation or to treat nicotine addiction with a doctor's prescription (which is largely the current position).

The objectives of, and rationale for, the proposal outlined in G/TBT/N/AUS/151 also apply to the broader proposal. Due to the health risks of vapes and the escalating use of vapes by young people, it is considered necessary to strictly control access to circumstances where a medical professional has assessed the need for the product (mainly for smoking cessation but also possibly to treat nicotine addiction if clinically appropriate). It is also considered necessary to impose quality standards to mitigate the health risks for lawful users and reduce the attractiveness of vapes to children and adolescents.